In the field of cell and gene therapy, lentiviral vector (LVV) manufacturing faces significant challenges, including high costs, scalability issues, and sensitivity to degradation. Traditional workflows often involve complex transfection processes, costly clarification steps, and inefficient downstream purification, limiting accessibility and commercial viability.
This application note provides insights about the synergistic benefits of combining our scale-X™ fixed-bed bioreactors with Isolere Bio‘s resin- and column-free affinity purification technology to design a simplified, cost-effective, end-to-end lentiviral vector manufacturing workflow.
Learn about process improvements that achieved:
- 26% reduction in total time (production in as little as 7 days)
- 49% reduction in consumables
- 27% reduction in cost